Search

Search Constraints

You searched for: Author/Creator Vo, Ashley A.

Search Results

1. A Phase I/II Placebo-Controlled Trial of C1-Inhibitor for Prevention of Antibody-Mediated Rejection in HLA Sensitized Patients. Issue 2 (February 2015)

2. A Phase I/II Trial of the Interleukin-6 Receptor–Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients. Issue 11 (November 2015)

3. CLAZAKIZUMAB (ANTI-IL-6 MONOCLONAL) TREATMENT OF PATIENTS WITH CHRONIC & ACTIVE ANTIBODY-MEDIATED REJECTION POST-KIDNEY TRANSPLANTATION (NCT03380377). Issue 3 (September 2020)

4. CLAZAKIZUMAB (ANTI-IL-6) INDUCES FOXP3+ TREGS IN HIGHLY HLA SENSITIZED PATIENTS RECEIVING HLAI KIDNEY TRANSPLANTATION (NCT03380962). Issue 3 (September 2020)

5. Clazakizumab for desensitization in highly sensitized patients awaiting transplantation. Issue 4 (30th December 2021)

6. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization. Issue 7 (July 2015)

7. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization. Issue 7 (July 2015)

8. Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes). Issue 8 (20th July 2021)

9. Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes). Issue 8 (August 2021)

10. Outcomes at 3 years posttransplant in imlifidase‐desensitized kidney transplant patients. Issue 12 (19th July 2021)